Does the media refer more to DYAI or IMDX?

In the previous week, Dyadic International had 2 more articles in the media than Oncocyte. MarketBeat recorded 4 mentions for Dyadic International and 2 mentions for Oncocyte. Dyadic International's average media sentiment score of 1.01 beat Oncocyte's score of 0.93 indicating that Dyadic International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyadic International 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oncocyte 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CNTB or DYAI?

In the previous week, Dyadic International had 2 more articles in the media than Connect Biopharma. MarketBeat recorded 4 mentions for Dyadic International and 2 mentions for Connect Biopharma. Connect Biopharma's average media sentiment score of 1.73 beat Dyadic International's score of 1.01 indicating that Connect Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Connect Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Dyadic International 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer UNCY or DYAI?

In the previous week, Unicycive Therapeutics and Unicycive Therapeutics both had 4 articles in the media. Dyadic International's average media sentiment score of 1.01 beat Unicycive Therapeutics' score of 0.56 indicating that Dyadic International is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Unicycive Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyadic International 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SPRB or DYAI?

In the previous week, Dyadic International had 1 more articles in the media than Spruce Biosciences. MarketBeat recorded 4 mentions for Dyadic International and 3 mentions for Spruce Biosciences. Spruce Biosciences' average media sentiment score of 1.89 beat Dyadic International's score of 1.01 indicating that Spruce Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spruce Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Dyadic International 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Dyadic International (DYAI) Competitors

$1.15 -0.04 (-3.36%)

As of 02:20 PM Eastern

Compare

DYAI vs. IMDX, CNTB, NGEN, UNCY, and SPRB

Should you buy Dyadic International stock or one of its competitors? MarketBeat compares Dyadic International with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Dyadic International include Oncocyte (IMDX), Connect Biopharma (CNTB), NervGen Pharma (NGEN), Unicycive Therapeutics (UNCY), and Spruce Biosciences (SPRB). These companies are all part of the "pharmaceutical products" industry.

How does Dyadic International compare to Oncocyte?

Dyadic International (NASDAQ:DYAI) and Oncocyte (NASDAQ:IMDX) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

Dyadic International currently has a consensus target price of $3.00, suggesting a potential upside of 160.87%. Oncocyte has a consensus target price of $12.00, suggesting a potential upside of 153.11%. Given Dyadic International's stronger consensus rating and higher probable upside, equities analysts clearly believe Dyadic International is more favorable than Oncocyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

28.0% of Dyadic International shares are owned by institutional investors. Comparatively, 55.4% of Oncocyte shares are owned by institutional investors. 20.9% of Dyadic International shares are owned by insiders. Comparatively, 2.2% of Oncocyte shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Dyadic International has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, Oncocyte has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market.

Dyadic International has a net margin of -192.40% compared to Oncocyte's net margin of -2,454.64%. Oncocyte's return on equity of 0.00% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyadic International	-192.40%	-1,005.45%	-77.64%
Oncocyte	-2,454.64%	N/A	-96.96%

Dyadic International has higher earnings, but lower revenue than Oncocyte. Dyadic International is trading at a lower price-to-earnings ratio than Oncocyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyadic International	$3.09M	13.56	-$7.36M	-$0.23	N/A
Oncocyte	$4.05M	37.80	-$50.22M	-$1.48	N/A

In the previous week, Dyadic International had 2 more articles in the media than Oncocyte. MarketBeat recorded 4 mentions for Dyadic International and 2 mentions for Oncocyte. Dyadic International's average media sentiment score of 1.01 beat Oncocyte's score of 0.93 indicating that Dyadic International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyadic International	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oncocyte	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Dyadic International beats Oncocyte on 10 of the 16 factors compared between the two stocks.

How does Dyadic International compare to Connect Biopharma?

Connect Biopharma (NASDAQ:CNTB) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

Connect Biopharma currently has a consensus price target of $7.29, suggesting a potential upside of 237.30%. Dyadic International has a consensus price target of $3.00, suggesting a potential upside of 160.87%. Given Connect Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Connect Biopharma is more favorable than Dyadic International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

58.7% of Connect Biopharma shares are held by institutional investors. Comparatively, 28.0% of Dyadic International shares are held by institutional investors. 22.6% of Connect Biopharma shares are held by insiders. Comparatively, 20.9% of Dyadic International shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Connect Biopharma has a net margin of 0.00% compared to Dyadic International's net margin of -192.40%. Connect Biopharma's return on equity of -122.29% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	-122.29%	-97.07%
Dyadic International	-192.40%	-1,005.45%	-77.64%

In the previous week, Dyadic International had 2 more articles in the media than Connect Biopharma. MarketBeat recorded 4 mentions for Dyadic International and 2 mentions for Connect Biopharma. Connect Biopharma's average media sentiment score of 1.73 beat Dyadic International's score of 1.01 indicating that Connect Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Connect Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Dyadic International	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dyadic International has higher revenue and earnings than Connect Biopharma. Dyadic International is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	$60K	2,266.56	-$55.48M	-$1.15	N/A
Dyadic International	$3.09M	13.56	-$7.36M	-$0.23	N/A

Connect Biopharma has a beta of -0.23, indicating that its share price is 123% less volatile than the broader market. Comparatively, Dyadic International has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market.

Summary

Connect Biopharma beats Dyadic International on 10 of the 16 factors compared between the two stocks.

How does Dyadic International compare to NervGen Pharma?

Dyadic International (NASDAQ:DYAI) and NervGen Pharma (NASDAQ:NGEN) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

NervGen Pharma has lower revenue, but higher earnings than Dyadic International. NervGen Pharma is trading at a lower price-to-earnings ratio than Dyadic International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyadic International	$3.09M	13.56	-$7.36M	-$0.23	N/A
NervGen Pharma	N/A	N/A	N/A	-$0.09	N/A

28.0% of Dyadic International shares are held by institutional investors. 20.9% of Dyadic International shares are held by company insiders. Comparatively, 5.8% of NervGen Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

NervGen Pharma has a net margin of 0.00% compared to Dyadic International's net margin of -192.40%. NervGen Pharma's return on equity of 0.00% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyadic International	-192.40%	-1,005.45%	-77.64%
NervGen Pharma	N/A	N/A	N/A

In the previous week, Dyadic International had 3 more articles in the media than NervGen Pharma. MarketBeat recorded 4 mentions for Dyadic International and 1 mentions for NervGen Pharma. Dyadic International's average media sentiment score of 1.01 beat NervGen Pharma's score of 0.82 indicating that Dyadic International is being referred to more favorably in the media.

Company	Overall Sentiment
Dyadic International	Positive
NervGen Pharma	Positive

Dyadic International currently has a consensus price target of $3.00, suggesting a potential upside of 160.87%. NervGen Pharma has a consensus price target of $14.00, suggesting a potential upside of 744.39%. Given NervGen Pharma's stronger consensus rating and higher probable upside, analysts clearly believe NervGen Pharma is more favorable than Dyadic International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

Summary

NervGen Pharma beats Dyadic International on 7 of the 13 factors compared between the two stocks.

How does Dyadic International compare to Unicycive Therapeutics?

Unicycive Therapeutics (NASDAQ:UNCY) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

Unicycive Therapeutics has a net margin of 0.00% compared to Dyadic International's net margin of -192.40%. Unicycive Therapeutics' return on equity of -134.69% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-134.69%	-84.51%
Dyadic International	-192.40%	-1,005.45%	-77.64%

40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 28.0% of Dyadic International shares are owned by institutional investors. 6.0% of Unicycive Therapeutics shares are owned by company insiders. Comparatively, 20.9% of Dyadic International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Unicycive Therapeutics and Unicycive Therapeutics both had 4 articles in the media. Dyadic International's average media sentiment score of 1.01 beat Unicycive Therapeutics' score of 0.56 indicating that Dyadic International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Unicycive Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyadic International	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dyadic International has higher revenue and earnings than Unicycive Therapeutics. Dyadic International is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	209.37	-$26.56M	-$2.21	N/A
Dyadic International	$3.09M	13.56	-$7.36M	-$0.23	N/A

Unicycive Therapeutics currently has a consensus price target of $21.75, indicating a potential upside of 318.43%. Dyadic International has a consensus price target of $3.00, indicating a potential upside of 160.87%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Unicycive Therapeutics is more favorable than Dyadic International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Unicycive Therapeutics has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market. Comparatively, Dyadic International has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market.

Summary

Unicycive Therapeutics beats Dyadic International on 9 of the 15 factors compared between the two stocks.

How does Dyadic International compare to Spruce Biosciences?

Spruce Biosciences (NASDAQ:SPRB) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

Spruce Biosciences presently has a consensus price target of $162.63, suggesting a potential upside of 275.45%. Dyadic International has a consensus price target of $3.00, suggesting a potential upside of 160.87%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, research analysts plainly believe Spruce Biosciences is more favorable than Dyadic International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Spruce Biosciences has a net margin of 0.00% compared to Dyadic International's net margin of -192.40%. Spruce Biosciences' return on equity of -155.40% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-155.40%	-101.67%
Dyadic International	-192.40%	-1,005.45%	-77.64%

In the previous week, Dyadic International had 1 more articles in the media than Spruce Biosciences. MarketBeat recorded 4 mentions for Dyadic International and 3 mentions for Spruce Biosciences. Spruce Biosciences' average media sentiment score of 1.89 beat Dyadic International's score of 1.01 indicating that Spruce Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spruce Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Dyadic International	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

91.7% of Spruce Biosciences shares are held by institutional investors. Comparatively, 28.0% of Dyadic International shares are held by institutional investors. 4.3% of Spruce Biosciences shares are held by insiders. Comparatively, 20.9% of Dyadic International shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Dyadic International has higher revenue and earnings than Spruce Biosciences. Dyadic International is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	N/A	N/A	-$38.97M	-$36.60	N/A
Dyadic International	$3.09M	13.56	-$7.36M	-$0.23	N/A

Spruce Biosciences has a beta of 3.16, suggesting that its share price is 216% more volatile than the broader market. Comparatively, Dyadic International has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market.

Summary

Spruce Biosciences beats Dyadic International on 9 of the 15 factors compared between the two stocks.

Get Dyadic International News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DYAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DYAI vs. The Competition

Export

Metric	Dyadic International	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$41.91M	$3.69B	$6.94B	$12.13B
Dividend Yield	N/A	2.18%	2.67%	9.80%
P/E Ratio	-5.00	21.65	27.14	23.72
Price / Sales	13.56	309.01	524.45	90.51
Price / Cash	N/A	59.51	26.39	46.67
Price / Book	38.33	8.01	10.47	6.17
Net Income	-$7.36M	$23.81M	$3.60B	$331.26M
7 Day Performance	-4.96%	-1.48%	-1.08%	-0.06%
1 Month Performance	43.57%	-3.40%	-2.40%	-2.50%
1 Year Performance	4.55%	34.61%	18.82%	13.75%

Dyadic International Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DYAI Dyadic International	2.968 of 5 stars	$1.15 -3.4%	$3.00 +160.9%	+8.2%	$41.91M	$3.09M	N/A	7	Positive News Short Interest Decrease
IMDX Oncocyte	2.4325 of 5 stars	$4.46 -2.8%	$12.00 +169.1%	N/A	$148.21M	$4.05M	N/A	120	High Trading Volume
CNTB Connect Biopharma	4.4766 of 5 stars	$2.36 +4.4%	$7.29 +208.7%	-3.6%	$142.30M	$60K	N/A	110	Positive News
NGEN NervGen Pharma	2.3754 of 5 stars	$1.74 -9.8%	$14.00 +704.6%	N/A	$140.30M	N/A	N/A	N/A	High Trading Volume
UNCY Unicycive Therapeutics	3.0227 of 5 stars	$5.22 +2.6%	$21.75 +316.7%	+10.9%	$139.43M	$680K	N/A	9

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DYAI) was last updated on 7/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dyadic International (DYAI) Competitors

DYAI vs. IMDX, CNTB, NGEN, UNCY, and SPRB

How does Dyadic International compare to Oncocyte?

Summary

How does Dyadic International compare to Connect Biopharma?

Summary

How does Dyadic International compare to NervGen Pharma?

Summary

How does Dyadic International compare to Unicycive Therapeutics?

Summary

How does Dyadic International compare to Spruce Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYAI vs. The Competition

Dyadic International Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dyadic International (DYAI) Competitors

DYAI vs. IMDX, CNTB, NGEN, UNCY, and SPRB

How does Dyadic International compare to Oncocyte?

Do analysts recommend DYAI or IMDX?

Do institutionals & insiders hold more shares of DYAI or IMDX?

Which has more volatility and risk, DYAI or IMDX?

Is DYAI or IMDX more profitable?

Which has preferable valuation & earnings, DYAI or IMDX?

Does the media refer more to DYAI or IMDX?

Summary

How does Dyadic International compare to Connect Biopharma?

Do analysts recommend CNTB or DYAI?

Do institutionals and insiders have more ownership in CNTB or DYAI?

Is CNTB or DYAI more profitable?

Does the media favor CNTB or DYAI?

Which has preferable earnings and valuation, CNTB or DYAI?

Which has more volatility & risk, CNTB or DYAI?

Summary

How does Dyadic International compare to NervGen Pharma?

Which has preferable valuation & earnings, DYAI or NGEN?

Do insiders & institutionals hold more shares of DYAI or NGEN?

Is DYAI or NGEN more profitable?

Does the media favor DYAI or NGEN?

Do analysts prefer DYAI or NGEN?

Summary

How does Dyadic International compare to Unicycive Therapeutics?

Is UNCY or DYAI more profitable?

Do insiders and institutionals have more ownership in UNCY or DYAI?

Does the media prefer UNCY or DYAI?

Which has stronger valuation & earnings, UNCY or DYAI?

Do analysts prefer UNCY or DYAI?

Which has more volatility & risk, UNCY or DYAI?

Summary

How does Dyadic International compare to Spruce Biosciences?

Do analysts recommend SPRB or DYAI?

Is SPRB or DYAI more profitable?

Does the media favor SPRB or DYAI?

Do institutionals and insiders have more ownership in SPRB or DYAI?

Which has stronger valuation & earnings, SPRB or DYAI?

Which has more risk and volatility, SPRB or DYAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYAI vs. The Competition

Dyadic International Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools